Cargando…
Pharmacovigilance and the Italian Medicines Agency
The new European Union (EU) regulations on pharmacovigilance require that the national systems are strengthened in order to fit the new requirements. The Italian Pharmacovigilance System, coordinated by the Italian Medicines Agency (AIFA), is made by local and regional structures. In 2007, a program...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853667/ https://www.ncbi.nlm.nih.gov/pubmed/24347980 http://dx.doi.org/10.4103/0976-500X.120940 |
_version_ | 1782294668288983040 |
---|---|
author | Pimpinella, Giuseppe Tartaglia, Loriana |
author_facet | Pimpinella, Giuseppe Tartaglia, Loriana |
author_sort | Pimpinella, Giuseppe |
collection | PubMed |
description | The new European Union (EU) regulations on pharmacovigilance require that the national systems are strengthened in order to fit the new requirements. The Italian Pharmacovigilance System, coordinated by the Italian Medicines Agency (AIFA), is made by local and regional structures. In 2007, a program for funding active pharmacovigilance projects in the Italian Regions was established by the National law. The AIFA is responsible for the preparation of guidelines aimed at the identification of research areas and for the approval of the projects submitted by the regions. In April 2012, the AIFA started a program of visits at the regional pharmacovigilance centers (RPCs), aimed at monitoring their performances, evaluating the quality of the activities in order to understand the main differences and discrepancies and with a view to start a program of harmonization of the procedures in place. The outcome of the visits program highlighted major differences among the quality management systems of the various centers; hence, AIFA has decided to launch an initiative to promote in the next months the harmonization of procedures. The synergy among AIFA, regional structures, RPCs, and local structure responsible for pharmacovigilance is needed in order to establish a robust pharmacovigilance system working in full compliance with the provisions of the new EU legislation. |
format | Online Article Text |
id | pubmed-3853667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-38536672013-12-16 Pharmacovigilance and the Italian Medicines Agency Pimpinella, Giuseppe Tartaglia, Loriana J Pharmacol Pharmacother Commentary The new European Union (EU) regulations on pharmacovigilance require that the national systems are strengthened in order to fit the new requirements. The Italian Pharmacovigilance System, coordinated by the Italian Medicines Agency (AIFA), is made by local and regional structures. In 2007, a program for funding active pharmacovigilance projects in the Italian Regions was established by the National law. The AIFA is responsible for the preparation of guidelines aimed at the identification of research areas and for the approval of the projects submitted by the regions. In April 2012, the AIFA started a program of visits at the regional pharmacovigilance centers (RPCs), aimed at monitoring their performances, evaluating the quality of the activities in order to understand the main differences and discrepancies and with a view to start a program of harmonization of the procedures in place. The outcome of the visits program highlighted major differences among the quality management systems of the various centers; hence, AIFA has decided to launch an initiative to promote in the next months the harmonization of procedures. The synergy among AIFA, regional structures, RPCs, and local structure responsible for pharmacovigilance is needed in order to establish a robust pharmacovigilance system working in full compliance with the provisions of the new EU legislation. Medknow Publications & Media Pvt Ltd 2013-12 /pmc/articles/PMC3853667/ /pubmed/24347980 http://dx.doi.org/10.4103/0976-500X.120940 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Pimpinella, Giuseppe Tartaglia, Loriana Pharmacovigilance and the Italian Medicines Agency |
title | Pharmacovigilance and the Italian Medicines Agency |
title_full | Pharmacovigilance and the Italian Medicines Agency |
title_fullStr | Pharmacovigilance and the Italian Medicines Agency |
title_full_unstemmed | Pharmacovigilance and the Italian Medicines Agency |
title_short | Pharmacovigilance and the Italian Medicines Agency |
title_sort | pharmacovigilance and the italian medicines agency |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853667/ https://www.ncbi.nlm.nih.gov/pubmed/24347980 http://dx.doi.org/10.4103/0976-500X.120940 |
work_keys_str_mv | AT pimpinellagiuseppe pharmacovigilanceandtheitalianmedicinesagency AT tartaglialoriana pharmacovigilanceandtheitalianmedicinesagency |